{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:34:43Z","timestamp":1780076083603,"version":"3.54.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.nrleng.2020.09.004","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T09:27:25Z","timestamp":1653643645000},"page":"229-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ocular myasthenia gravis and risk factors for developing a secondary generalisation: description of a Spanish series"],"prefix":"10.1016","volume":"38","author":[{"given":"I.","family":"D\u00edaz-Maroto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"S\u00e1nchez-Ayaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alcahut-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gonz\u00e1lez-Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Pardal-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2020.09.004_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","article-title":"Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification","volume":"36","author":"Wong","year":"2016","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0020","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial effects of corticosteroids on ocular myasthenia gravis","volume":"53","author":"Kupersmith","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppresive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","article-title":"Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients","volume":"273","author":"Hong","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0040","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","article-title":"Prognosis of ocular myasthenia gravis: retrospective multicenter analysis","volume":"122","author":"Nagia","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0045","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.4103\/0366-6999.166032","article-title":"Clinical features and prognosis of ocular myasthenia gravis patients with different phenotypes","volume":"128","author":"Wang","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0050","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.25971","article-title":"Ocular presentation of myasthenia gravis: a natural history cohort","volume":"57","author":"Kamarajah","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fneur.2018.00077","article-title":"Clinical characteristics of juvenile myasthenia gravis in Southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"Mazzoli","year":"2018","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0065","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/mus.25983","article-title":"Low conversion rate of ocular to generalized myasthenia gravis in Singapore","volume":"57","author":"Teo","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000487132","article-title":"Prognosis of ocular myasthenia gravis in an Argentinian population","volume":"79","author":"Aguirre","year":"2018","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0075","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","article-title":"Antibody profile may predict outcome in ocular myasthenia gravis","volume":"118","author":"Galassi","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/acn3.692","article-title":"miR-30e-5p as predictor of generalization in ocular myasthenia gravis","volume":"6","author":"Sabre","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0085","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","article-title":"Generalization after ocular onset in myasthenia gravis: a case series in Germany","volume":"265","author":"Li","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0090","first-page":"30197","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population based study","volume":"9934","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","article-title":"Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody","volume":"109","author":"Apinyawasisuk","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0105","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","article-title":"Ocular myasthenia gravis: controversies and updates","volume":"14","author":"Wong","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WCO.0000000000000775","article-title":"Ocular myasthenia gravis: updates on an elusive target","volume":"33","author":"Melson","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","article-title":"Clinical predictors for the prognosis of myasthenia gravis","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nrl.2014.09.007","article-title":"Prevalencia de la miastenia gravis en la comarca de Osona (Barcelona, Catalu\u00f1a)","volume":"32","author":"Aragon\u00e9s","year":"2017","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/0014-4886(92)90201-Z","article-title":"Glucocorticoid increases acetylcholinesterase and organization of the postsynaptic membrane in innervated cultured human muscle","volume":"115","author":"Askanas","year":"1992","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/WNO.0000000000000270","article-title":"Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients?","volume":"36","author":"Wong","year":"2016","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular mysthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0145","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s10072-017-3058-7","article-title":"Thymectomy is a beneficial therapy for patients with nonthymomatous ocular myasthenia gravis: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nrleng.2020.09.004_bib0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British Neurologist\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580822000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580822000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:35:25Z","timestamp":1761881725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580822000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2173580822000530"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2020.09.004","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular myasthenia gravis and risk factors for developing a secondary generalisation: description of a Spanish series","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2020.09.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}